{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:30Z","timestamp":1789434150889,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,28]],"date-time":"2006-07-28T00:00:00Z","timestamp":1154044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>In patients with advanced\u2010stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>The German Low\u2010Grade Lymphoma Study Group performed a randomized trial comparing combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) chemotherapy with combined mitoxantrone, chlorambucil, and prednisone (MCP) chemotherapy as first\u2010line therapy for patients with advanced\u2010stage FL or MCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Three hundred sixty\u2010three patients with advanced\u2010stage FL (<jats:italic>n<\/jats:italic> = 277 patients) or MCL (<jats:italic>n<\/jats:italic> = 86 patients) entered the trial and were evaluable fully. CHOP resulted in a significantly higher overall response rate in patients with FL (91% vs. 82%; <jats:italic>P<\/jats:italic> = .026) and a similar tendency in patients with MCL (87% vs. 73%; <jats:italic>P<\/jats:italic> = .080). However, no significant differences were observed in the time to treatment failure or in overall survival. CHOP produced significantly more nonhematologic toxicities, whereas MCP was associated with more severe hematologic side effects. The proportion of patients who successfully underwent peripheral blood stem cell collection was significantly lower after MCP (44% vs. 93% after CHOP; <jats:italic>P<\/jats:italic> = .0003).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Taking into account that, currently, chemotherapy regularly is combined with rituximab as first\u2010line therapy for FL and MCL, the data from this study may have an impact on the type of chemotherapy to be applied in such combinations. Particularly in younger, high\u2010risk patients who are candidates for autologous stem cell transplantation, CHOP should be preferred over MCP. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22093","type":"journal-article","created":{"date-parts":[[2006,7,28]],"date-time":"2006-07-28T18:01:01Z","timestamp":1154109661000},"page":"1014-1022","source":"Crossref","is-referenced-by-count":76,"title":["Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas"],"prefix":"10.1002","volume":"107","author":[{"given":"Christina","family":"Nickenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Trumper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Wandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lengfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_5_3_2","first-page":"354","article-title":"Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial (G.E.L.A. Study Group)","volume":"102","author":"Sebban C","year":"2003","journal-title":"Blood."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.32748"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.004"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.172"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01692.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0581-1"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA\u2010GOELAMS FL\u20102000 randomized trial in 359 patients","volume":"104","author":"Salles GA","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00195368"},{"key":"e_1_2_5_15_2","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low\u2010grade non\u2010Hodgkin's lymphoma. German Low\u2010Grade Lymphoma Study Group","volume":"10","author":"Unterhalt M","year":"1996","journal-title":"Leukemia."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"issue":"6","key":"e_1_2_5_17_2","first-page":"20","article-title":"Treatment of low\u2010grade non\u2010Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine\/mitoxantrone followed by interferon alpha\u20102b maintenance: results of a clinical Phase II study","volume":"17","author":"Hiddemann W","year":"1990","journal-title":"Semin Oncol."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.14.1138"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990915\/30)18:17\/18<2271::AID-SIM254>3.0.CO;2-Z"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6112.533"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.644"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.128"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00142-9"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.1985.3.3.299","article-title":"Karnofsky Memorial Lecture. The low\u2010grade non\u2010Hodgkin's lymphomas: challenges and opportunities","volume":"3","author":"Rosenberg SA","year":"1985","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"issue":"6","key":"e_1_2_5_27_2","first-page":"30","article-title":"Chemotherapy sensitization by rituximab: experimental and clinical evidence","volume":"27","author":"Wilson WH","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_5_28_2","first-page":"33","article-title":"Anti\u2010CD20 antibody (IDEC\u2010C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","journal-title":"Haematologica."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.016"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22093","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:23:08Z","timestamp":1760268188000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22093"}},"subtitle":["Results of a prospective randomized trial of the German Low\u2010Grade Lymphoma Study Group"],"short-title":[],"issued":{"date-parts":[[2006,7,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1002\/cncr.22093"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22093","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,28]]}}}